Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 50/100

Appendix 3Y Change of Director ' s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and docum

Wednesday, September 17, 2025 4 min read
Key Takeaway: Alterity Therapeutics Limited has filed a Change of Director's Interest Notice with the ASX, reporting no acquisitions or disposals of securities by directors. The notice includes updates on the number of securities held by various directors, with some options expiring. The filing emphasizes compliance with ASX regulations and the need for timely reporting of changes in director interests.

Market Sentiment Analysis

CONCERNS & RISKS

  • No new acquisitions of securities reported.
  • Expired options may indicate lack of director confidence.
  • Absence of changes in director's interests may affect investor perception.

Full Press Release Details

Appendix 3Y
Change of Director ' s Interest Notice
Change of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's
property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Brian Meltzer
Date of last notice 24 April 2025
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in the
trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Direct (2) Indirect - BT PORTFOLIO SERVICES
Nature of indirect interest (including registered holder) (1) N/A (2) SMSF
Date of change (1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) 17 September 2025 (2) N/A
No. of securities held prior to change (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES
(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01
(1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028
(1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01
(1.5) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09
(2) 326,666 - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director ' s Interest Notice
Class (1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.5) UNLISTED OPT EXP 17/09/2025 @ $0.09 (2) FULLY PAID ORDINARY SHARES
Number acquired (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) NIL (2) NIL
Number disposed (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) (7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09) (2) NIL
Value/Consideration (1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) NIL CONSIDERATION (2) N/A
No. of securities held after change (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES (1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 (1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028 (1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.5) NIL - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2) 326,666 - FULLY PAID ORDINARY SHARES
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director ' s Interest Notice
Nature of change (1.1) N/A
(1.2) N/A
(1.3) N/A
(1.4) N/A
(1.5) Option Expired
(2) N/A
Part 2 - Change of director's relevant interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director ' s Interest Notice
Change of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's
property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Geoffrey Kempler
Date of last notice 30 December 2024
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in the
trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Direct (2) Indirect - NRB Developments Pty Ltd (3) Indirect - Sadarajak Pty Ltd (4) Direct (5) Indirect - Baywick Pty Ltd (6) Indirect - Crystal Triangle Pty Ltd
Nature of indirect interest (including registered holder) (1) N/A (2) Director related entity
(3) Director related entity
(4) N/A
(5) Director related entity
(6) Director related entity
Date of change (1.1) N/A
(1.2) 17 September 2025
(2) N/A
(3) N/A
(4) N/A
(5) N/A
(6) N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director ' s Interest Notice
No. of securities held prior to change (1.1) 60,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.2) 14,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2) 2,970,000 - FULLY PAID ORDINARY SHARES (3) 756,000 - FULLY PAID ORDINARY SHARES (4) 30,000 - FULLY PAID ORDINARY SHARES (5) 14,165,000 - FULLY PAID ORDINARY SHARES (6) 90,000 - FULLY PAID ORDINARY SHARES
Class (1.1) UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.2) UNLISTED OPT EXP 17/09/2025 @ $0.09 (2) FULLY PAID ORDINARY SHARES (3) FULLY PAID ORDINARY SHARES (4) FULLY PAID ORDINARY SHARES (5) FULLY PAID ORDINARY SHARES (6) FULLY PAID ORDINARY SHARES
Number acquired (1.1) NIL (1.2) NIL (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL
Number disposed (1.1) NIL (1.2) (14,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09) (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL
Value/Consideration (1.1) N/A (1.2) NIL CONSIDERATION (2) N/A (3) N/A (4) N/A (5) N/A (6) N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director ' s Interest Notice
No. of securities held after change (1.1) 60,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.2) NIL - UNLISTED OPT EXP 17/09/2025 @ $0.09 (2) 2,970,000 - FULLY PAID ORDINARY SHARES (3) 756,000 - FULLY PAID ORDINARY SHARES (4) 30,000 - FULLY PAID ORDINARY SHARES (5) 14,165,000 - FULLY PAID ORDINARY SHARES (6) 90,000 - FULLY PAID ORDINARY SHARES
Nature of change (1.1) N/A (1.2) Option Expired (2) N/A (3) N/A (4) N/A (5) N/A (6) N/A
Part 2 - Change of director's relevant interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director ' s Interest Notice
Change of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's
property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Lawrence Gozlan
Date of last notice 24 April 2025
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in the
trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest (1) Indirect - Montoya Pty Ltd <Buttercup A/C>
Nature of indirect interest (including registered holder) (1) Director
Date of change (1.1) N/A
(1.2) 17 September 2025
(1.3) N/A
(1.4) N/A
No. of securities held prior to change (1.1) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01
(1.2) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09
(1.3) 4,545,455 - FULLY PAID ORDINARY SHARES
(1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028
Class (1.1) UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.2) UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.3) FULLY PAID ORDINARY SHARES (1.4) LISTED OPT EXP 26/02/2027 @ $0.028
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director ' s Interest Notice
Number acquired (1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL
Number disposed (1.1) NIL (1.2) (7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09) (1.3) NIL (1.4) NIL
Value/Consideration (1.1) N/A (1.2) NIL CONSIDERATION (1.3) N/A (1.4) N/A
No. of securities held after change (1.1) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01 (1.2) NIL - UNLISTED OPT EXP 17/09/2025 @ $0.09 (1.3) 4,545,455 - FULLY PAID ORDINARY SHARES (1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028
Nature of change (1.1) N/A (1.2) Option Expired (1.3) N/A (1.4) N/A
Part 2 - Change of director's relevant interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Were the interests in the securities or c+ontracts detailed above traded during a closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director ' s Interest Notice
Change of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's
property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director Peter Marks
Date of last notice 24 April 2025
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in the
trust made available by the responsible entity of the trust

Frequently Asked Questions

What is the purpose of a Change of Director's Interest Notice?

It's to inform the ASX of changes in a director's interests as per regulations.

Who submitted the notice for Alterity Therapeutics Limited?

The notice was submitted on behalf of the directors to comply with ASX rules.

When was the Change of Director's Interest Notice last updated?

The notice was last updated on 1 January 2011.

What happens to the information given to ASX?

The information becomes ASX's property and may be publicly disclosed.

What is the requirement for closed period trading?

Trading during a closed period needs prior written clearance from ASX.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics ASX director interests corporate filings
Last updated: Sep 17, 2025